Biomedical or Dental Material

Merck Continues Cuts: 204 Employees Laid Off in New Jersey

3 weeks ago talkbio0Tagged Biopharma Industry, Cautionary Warning, cost-cutting, Dosage Forms, Gardasil, global workforce reduction, Keytruda, layoffs, Merck, New Jersey, Rahway, restructuring

Merck; layoffs; New Jersey; Rahway; pharmaceutical; cost-cutting; restructuring; WARN notice; global workforce reduction; Keytruda; Gardasil; biopharma industry

Santen Announces Completion of Share Buyback

1 month ago talkbio0Tagged buyback, Dosage Forms, equity buyback, Japanese language, Occupational activity of managing finances, repurchase, Santen, shareholder value

Santen Pharmaceutical; share buyback; repurchase; equity buyback; shareholder value; Japanese pharmaceuticals; financial management

Dr. Andreas Wallnöfer Named to Optigo Biotherapeutics Board of Directors

1 month ago talkbio0Tagged Andreas Wallnöfer, Biotechnology, board of directors, Dosage Forms, Drug Development, Hyaluronic Acid anchoring platform, IND-enabling studies, Ophthalmology specialty, Optigo Biotherapeutics, R&D, Retinal Diseases

Andreas Wallnöfer; Optigo Biotherapeutics; Board of Directors; ophthalmology; biotechnology; retinal diseases; IND-enabling studies; Hyaluronic Acid anchoring platform; pharmaceutical R&D; drug development

Weight-loss drug stocks drop after Trump pledges major price cuts

2 months ago talkbio0Tagged Administration occupational activities, Drops - Drug Form, drug price, eli lilly, Glucagon-Like Peptide 1, Nordisk, Ozempic, Wegovy, Weight-Loss Agents

weight-loss drugs; ozempic; wegovy; novo nordisk; eli lilly; stock drop; drug pricing; trump administration; GLP-1

Ono Pharmaceutical and Jorna Therapeutics Announce AI-Driven Research Pact to Develop Novel RNA Editing Medications

3 months ago talkbio0Tagged Artificial Intelligence, Dosage Forms, Japan, Jorna, RNA Editing, SkyEngine

Ono Pharmaceutical; Jorna Therapeutics; RNA editing; AI drug discovery; SkyEngine; biotech partnership; Japan

AbbVie Buys Gilgamesh’s Psychedelic Drug Bretisilocin for $1.2B

4 months ago talkbio0Tagged AbbVie, Acquisition, bretisilocin, Dosage Forms, Gilgamesh, GM-2505, Hallucinogens, mental health, Neuroscience discipline

AbbVie; Gilgamesh Pharmaceuticals; psychedelic drug; bretisilocin; GM-2505; major depressive disorder; acquisition; mental health; neuroscience; pharmaceutical deal

IO Biotech’s cancer vaccine Cylembio narrowly misses Phase III primary endpoint in advanced melanoma, but company eyes FDA filing in 2025

4 months ago talkbio0Tagged biotech, Blackfoot language, Clinical Trials, Cylembio, Drops - Drug Form, etimupepimut, Hazard Ratio, Io satellite, Keytruda, melanoma, Overall Survival, P-Value, pembrolizumab, Phase 3, Progression-Free Survival, United States Food and Drug Administration

Cylembio; IO Biotech; melanoma; Phase 3; pivotal trial; progression-free survival (PFS); hazard ratio 0.77; p-value 0.056; Keytruda (pembrolizumab); FDA BLA; overall survival (OS) trend; IOB-013/KN-D18; NCT05155254; imsapepimut; etimupepimut; stock drop

XtalPi and DoveTree Announce Landmark $6 Billion AI-Powered Drug Discovery Collaboration

4 months ago talkbio0Tagged Artificial Intelligence, Collaboration, Dosage Forms, DoveTree Medicines, Drug Discovery, Gregory Verdine, Immunology, Metabolic Diseases, milestone payments, Neoplasms, Neurology speciality, Robotics, royalties, upfront payment, XtalPi

XtalPi; DoveTree Medicines; AI drug discovery; robotics; pharmaceutical R&D; Gregory Verdine; oncology; immunology; neurology; metabolic diseases; collaboration; upfront payment; milestone payments; royalties

FDA Approves LENZ Therapeutics’ VIZZ Eye Drop for Presbyopia

4 months ago talkbio0Tagged aceclidine, Approved, Eye Drops, LENZ, Myopia, presbyopia, United States Food and Drug Administration, VIZZ

FDA approval; VIZZ; LENZ Therapeutics; presbyopia; aceclidine; eye drop; near vision

Novo Nordisk’s Leadership Shakeup and Wider Implications; Ex-FDA Official Takes Regulatory Role at GSK

4 months ago talkbio0Tagged CEO, competition, Drops - Drug Form, drug market, Leadership, Maziar Mike Doustdar, Nordisk, Obesity, Prices, Regulatory Affairs, Shakeup, SmithKline Beecham, United States Food and Drug Administration

Novo Nordisk; leadership shakeup; new CEO; Maziar Mike Doustdar; share price drop; obesity drug market; competition; GSK; regulatory affairs; Former FDA